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Use of Intravascular Imaging During Chronic Total Occlusion
Percutaneous Coronary Intervention: Insights From a Contemporary
Multicenter Registry
Judit Karacsonyi, MD; Khaldoon Alaswad, MD; Farouc A. Jaffer, MD, PhD; Robert W. Yeh, MD; Mitul Patel, MD; John Bahadorani, MD;
Aris Karatasakis, MD; Barbara A. Danek, MD; Anthony Doing, MD; J. Aaron Grantham, MD; Dimitri Karmpaliotis, MD; Jeffrey W. Moses, MD;
Ajay Kirtane, MD; Manish Parikh, MD; Ziad Ali, MD; William L. Lombardi, MD; David E. Kandzari, MD; Nicholas Lembo, MD; Santiago Garcia,
MD; Michael R. Wyman, MD; Aya Alame, BA; Phuong-Khanh J. Nguyen-Trong, MD; Erica Resendes, MS; Pratik Kalsaria, MS; Bavana V.
Rangan, BDS, MPH; Imre Ungi, MD; Craig A. Thompson, MD, MMSc; Subhash Banerjee, MD; Emmanouil S. Brilakis, MD, PhD
Background-—Intravascular imaging can facilitate chronic total occlusion (CTO) percutaneous coronary intervention.
Methods and Results-—We examined the frequency of use and outcomes of intravascular imaging among 619 CTO percutaneous
coronary interventions performed between 2012 and 2015 at 7 US centers. Mean age was 65.410 years and 85% of the patients
were men. Intravascular imaging was used in 38%: intravascular ultrasound in 36%, optical coherence tomography in 3%, and both
in 1.45%. Intravascular imaging was used for stent sizing (26.3%), stent optimization (38.0%), and CTO crossing (35.7%, antegrade
in 27.9%, and retrograde in 7.8%). Intravascular imaging to facilitate crossing was used more frequently in lesions with proximal cap
ambiguity (49% versus 26%, P<0.0001) and with retrograde as compared with antegrade-only cases (67% versus 31%, P<0.0001).
Despite higher complexity (Japanese CTO score: 2.861.19 versus 2.431.19, P=0.001), cases in which imaging was used for
crossing had similar technical and procedural success (92.8% versus 89.6%, P=0.302 and 90.1% versus 88.3%, P=0.588,
respectively) and similar incidence of major cardiac adverse events (2.7% versus 3.2%, P=0.772). Use of intravascular imaging was
associated with longer procedure (192 minutes [interquartile range 130, 255] versus 131 minutes [90, 192], P<0.0001) and
fluoroscopy (71 minutes [44, 93] versus 39 minutes [25, 69], P<0.0001) time.
Conclusions-—Intravascular imaging is frequently performed during CTO percutaneous coronary intervention both for crossing and
for stent selection/optimization. Despite its use in more complex lesion subsets, intravascular imaging was associated with similar
rates of technical and procedural success for CTO percutaneous coronary intervention.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02061436. ( J Am Heart Assoc. 2016;5:
e003890 doi: 10.1161/JAHA.116.003890)
Key Words: chronic total occlusion • intravascular ultrasound • optical coherence tomography • percutaneous coronary
intervention
U se of intravascular ultrasound (IVUS) for stent optimiza-tion during chronic total occlusion percutaneous
coronary intervention (CTO PCI) has been shown to improve
long-term outcomes,1–3 yet its impact on crossing has
received limited study.1–9 Intravascular imaging can help
resolve proximal cap ambiguity by identifying the position of
the main branch10 and clarifying guidewire position during
both antegrade and retrograde CTO crossing attempts.11
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IVUS can determine optimal balloon sizing for the reverse
controlled antegrade and retrograde tracking and dissection
(reverse CART) technique.11,12 Moreover, intravascular imag-
ing can facilitate sizing of balloons and stents and optimize
stent expansion and stent strut apposition.13 We examined a
large multicenter contemporary CTO PCI registry to determine
the frequency of intravascular imaging use during CTO PCI
and the associated procedural outcomes.
Methods
Patient Population
We analyzed the frequency of use and outcomes of intravas-
cular imaging among 619 chronic CTO PCIs performed
between 2012 and 2015 at 7 US centers: Appleton Cardiol-
ogy, Appleton Wisconsin; Henry Ford Hospital, Detroit,
Michigan; Massachusetts General Hospital, Boston, Mas-
sachusetts; Medical Center of the Rockies, Loveland, Color-
ado; St. Luke’s Health System’s Mid-America Heart Institute,
Kansas City, Missouri; VA North Texas Health Care System,
Dallas, Texas; and VA San Diego Healthcare System, San
Diego, California.
Enrollment was performed during only part of the study
period in some centers due to participation in other studies.
Data collection was performed both prospectively and retro-
spectively and was recorded in a dedicated online database
(PROGRESS CTO: Prospective Global Registry for the Study of
Chronic Total Occlusion Intervention, Clinicaltrials.gov Identi-
fier: NCT02061436).14–24 The study was approved by the
institutional review board of each site and a waiver of
informed consent was obtained.
Definitions
Coronary CTOs were defined as coronary lesions with
Thrombolysis In Myocardial Infarction grade 0 flow of at least
3-month duration.25 Estimation of the occlusion duration was
based on first onset of anginal symptoms, prior history of
myocardial infarction in the target vessel territory, or
comparison with a prior angiogram. Calcification was
assessed by angiography as mild (spots), moderate (involving
≤50% of the reference lesion diameter), and severe (involving
>50% of the reference lesion diameter). Moderate proximal
vessel tortuosity was defined as the presence of at least 2
bends >70° or 1 bend >90° and severe tortuosity as 2 bends
>90° or 1 bend >120° in the CTO vessel. The Japanese
Chronic Total Occlusion score was calculated as described by
Morino et al.26 The Progress CTO score was calculated as
described by Christopoulos et al.22 Technical success was
defined as successful CTO revascularization with achievement
of <30% residual diameter stenosis within the treated
segment and restoration of Thrombolysis In Myocardial
Infarction grade 3 antegrade flow. Procedural success was
defined as achievement of technical success with no in-
hospital major adverse cardiac events (MACE). In-hospital
MACE included any of the following adverse events prior to
hospital discharge: death, myocardial infarction, urgent repeat
target vessel revascularization with either PCI or coronary
artery bypass graft surgery, tamponade requiring either
pericardiocentesis or surgery, and stroke. Myocardial infarc-
tion was defined using the Third Universal Definition of
Myocardial Infarction.27
Statistical Analysis
The primary comparison of the study was between procedures
in which intravascular imaging (IVUS and/or optical coher-
ence tomography [OCT]) was used versus those in which it
was not used for crossing the occlusion (Figure 1). In a
secondary analysis of cases that were successfully crossed
with a guidewire, a comparison was made between use versus
no use of intravascular imaging for stent sizing/optimization.
Continuous variables were presented as meanSD or
median (interquartile range) and were compared using the t
test, or Wilcoxon rank-sum test, as appropriate. Categorical
data were reported as frequencies or percentages and
compared using the v2 test or Fisher’s exact test, as
appropriate. The baseline clinical characteristics and the
procedural outcomes were analyzed among the patients (606
patients), while the angiographic characteristics were ana-
lyzed among procedures (619 procedures). All statistical
analyses were performed with JMP 11.0 (SAS Institute,
Cary, NC). Two-sided P<0.05 were considered statistically
significant.
Results
Baseline Patient and Procedural Characteristics
A total of 619 CTO PCI procedures performed in 606 patients
were included in the present analysis. The baseline patient
and angiographic characteristics of the study population are
summarized in Table 1. Mean age was 65.410 years and
85% of the patients were men with high prevalence of
diabetes (50%), dyslipidemia (92%), and hypertension (88%).
Approximately one third had congestive heart failure (33%) or
prior coronary artery bypass graft surgery (32%).
Intravascular imaging was used in 38% of the procedures,
as follows: IVUS in 36%, OCT in 3%, and both in 1.45%. The
indications for intravascular imaging were to facilitate CTO
crossing (overall 35.7%, antegrade in 27.9%, and retrograde in
7.8%) and stent sizing (26.3%) or optimization (38.0%)
(Figure 2). Wide variability was observed in the frequency of
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intravascular imaging use among various centers (0–58%,
Figure 3).
Intravascular Imaging for Crossing
The baseline clinical and angiographic characteristics of
patients who did and those who did not undergo intravas-
cular imaging for crossing were similar (Tables 1 and 2). The
most common CTO PCI target vessel was the right coronary
artery (52%), followed by the left anterior descending artery
(26%), and the left circumflex (22%). Moderate to severe
calcification and moderate to severe tortuosity were present
in 53% and 42%, respectively. Procedural outcomes are
summarized in Table 3. Overall technical and procedural
rates were 90.1% and 88.6%, respectively. Antegrade wiring
was the successful crossing strategy in 48% of the cases,
antegrade dissection and re-entry in 23%, and the retrograde
approach in 23%.
Intravascular imaging for crossing was used more com-
monly in lesions with proximal cap ambiguity (49% versus
26%, P<0.0001), side branch at the proximal cap (61% versus
47%, P=0.035), longer occlusion length (30 mm [interquartile
range: 22, 50] versus 28 mm [15, 44], P=0.009), and higher
Japanese Chronic Total Occlusion (2.861.19 versus
2.431.19, P=0.001) and Progress CTO (1.641.00 versus
1.181.02, P<0.0001) score. Cases in which intravascular
imaging was used for crossing were more likely to succeed
using the retrograde approach or antegrade dissection and
reentry (47% versus 17% and 25% versus 23%), as compared
with antegrade wiring (23% versus 53%, P<0.0001).
Procedural outcomes are summarized in Table 3 and
Figure 4. Technical and procedural success were similar in
cases in which intravascular imaging was used for crossing
(92.8% versus 89.6%, P=0.302 and 90.1% versus 88.3%,
P=0.588, respectively), whereas the incidence of MACE was
similarly low in both groups (2.7% versus 3.2%, P=0.772).
Success and complication rates were similar among centers
with high versus low intravascular imaging use (data not
shown). There was no significant difference in the incidence of
death, myocardial infarction, repeated PCI, stroke, and
pericardiocentesis. Mean procedure duration was significantly
longer among procedures in which intravascular imaging was
used for crossing (192 minutes [130, 255] versus 131 min-
utes [90, 192], P<0.0001), as was median fluoroscopy time
(71 minutes [44, 93] versus 39 minutes [25, 69], P<0.0001),
mean air kerma radiation dose (4.98 Gray [3.11, 6.04] versus
3.42 Gray [2.09, 5.09], P<0.0001), and median contrast
volume (310 mL [240, 400] versus 270 mL [200, 360],
P=0.004) as compared with cases in which intravascular
imaging was not used.
Figure 1. Flow chart of the study. CTO indicates chronic total occlusion; PCI, percutaneous coronary
intervention.
DOI: 10.1161/JAHA.116.003890 Journal of the American Heart Association 3
Intravascular Imaging in CTO PCI Karacsonyi et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Intravascular Imaging for Stent Sizing and/or
Optimization
Among CTOs successfully crossed with a guidewire, cases in
which imaging was used for stent sizing and optimization were
more complex, as reflected by higher Japanese Chronic Total
Occlusion (2.651.17 versus 2.381.22, P=0.013) and
Progress CTO (1.391.09 versus 1.190.98, P=0.035)
scores (Tables 4 and 5). They were also more likely to have
moderate/severe calcification (63% versus 47%, P=0.001),
longer occlusion length (30 mm [20, 50] versus 28 mm [15,
40], P=0.030) or be due to in-stent restenosis (23% versus
14%, P=0.015) and required longer procedure (162 minutes
[113, 216] versus 133 minutes [91, 201], P=0.001) and
fluoroscopy (52 minutes [33, 81] versus 40 minutes [26, 73],
P=0.014) time with a trend for higher air kerma radiation dose
(3.90 Gray [2.48, 5.46] versus 3.48 Gray [2.13, 5.34],
P=0.249) and contrast volume (300 mL [228, 368] versus
277 mL [200, 370], P=0.106). Use of intravascular imaging
was associated with similar technical (97.7% versus 97.5%,
P=0.854) and procedural (97.1% versus 95.4%, P=0.347)
success rates and similarly low MACE rates (2.3% versus
3.1%, P=0.622) (Figure 5). There was a trend toward larger
number of stents in procedures where intravascular imaging
was used for stent sizing/and/or optimization (2.71.3
versus 2.51.2, P=0.07).
Discussion
The main findings of our study are that intravascular imaging
is frequently performed during CTO PCI both for crossing and
for stent selection/optimization. Intravascular imaging was
used in more complex occlusions and was associated with
similarly high success rates, but longer procedure time and
higher radiation dose.
Frequency of Intravascular Imaging Use in CTO
PCI
In our study, intravascular imaging was used in 38% of CTO
PCI cases, which is similar to 39% utilization in the Multicenter
Korean CTO Registry.1 Okamura et al reported use of IVUS in
47.5% of patients in their study about complications during
retrograde approach in the Japanese Multicenter CTO Registry
IVUS.28 In contrast, in the European Registry of Chronic Total
Occlusion, IVUS use was significantly lower (2.9% overall29
and 9.2% in retrograde cases30), suggesting that imaging use
may be low even among experienced operators and centers.
Habara et al31 compared CTO PCI outcomes according to
operator experience: when using the antegrade approach
after retrograde failure, the success rate of IVUS-guided
techniques was significantly higher in higher-volume centers
than lower-volume centers (13.3% versus 3.3%; P=0.018).
Therefore, IVUS guidance for antegrade crossing requires high
operator skill and experience.32 Moreover, the cost of
catheters and the additional time required for obtaining and
interpreting the images can affect the use of intravascular
imaging and may explain the wide variability in its use for CTO
(and non-CTO) PCI.
Selection of Intravascular Imaging Modality for
CTO PCI
IVUS was the intravascular imaging modality used in most
CTO PCIs, and in contrast to OCT, does not require flushing of
Table 1. Baseline Clinical Characteristics of the Study
Patients, Classified According to Whether Intravascular
Imaging Was Used to Guide CTO Crossing or Not
Variable
Overall
Imaging
for
Crossing
No Imaging
or Imaging
for Stent
Optimization
P-Value(n=606) (n=111) (n=495)
Age, y* 65.410 6510 6610 0.466
Men 85% 91% 84% 0.066
BMI, kg/m2* 30.66 31.77 30.46 0.058
Diabetes mellitus 50% 58% 49% 0.069
Hypertension 88% 88% 88% 0.908
Dyslipidemia 92% 94% 92% 0.631
Smoking
(current)
23% 77% 77% 0.908
LVEF (%)* 5115 4815 5115 0.056
Family history of
CAD
24% 24% 24% 0.897
Congestive heart
failure
33% 37% 32% 0.29
Prior myocardial
infarction
45% 46% 44% 0.793
Prior CABG 32% 41% 30% 0.024
Prior CVD 11% 8% 12% 0.331
Prior PVD 15% 12% 15% 0.403
Baseline
creatinine,
mg/dL†
1.0
(0.8, 1.2)
1.0
(0.9, 1.3)
1.0
(0.8, 1.2)
0.615
Imaging for crossing: cases in which intravascular imaging was used for crossing the
chronic total occlusion. No imaging or imaging for stent optimization: cases in which
intravascular imaging was not used or cases in which intravascular imaging was used for
stent optimization. BMI indicates body mass index; CABG, coronary artery bypass
grafting; CAD, coronary artery disease; CTO, chronic total occlusion; CVD,
cerebrovascular disease; LVEF, left ventricular ejection fraction; PCI, percutaneous
coronary intervention; PVD, peripheral vascular disease.
*MeanSD.
†Median (interquartile range).
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the blood column within the arterial lumen and has higher
penetration depth. OCT performed before stenting could also
cause subintimal hematoma due to the need for contrast
administration for image acquisition. OCT, however, offers
superior resolution compared to IVUS and has been used in
CTO PCI to determine guidewire position and stent optimiza-
tion after deployment. The ALSTER OCT-CTO (AskLepios ST.
GEoRg’s Hospital-Optical Coherence Tomography for follow-
Figure 2. Use of intravascular imaging during chronic total occlusion percutaneous coronary intervention.
CART indicates controlled antegrade and retrograde tracking and dissection.
Figure 3. Frequency of intravascular imaging use at the study participating centers. The absolute number
of the cases with intravascular imaging use is listed in parentheses.
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up of Chronic Total Occlusions) registry reported a signif-
icantly higher rate of uncovered and malapposed stent struts
in CTOs as compared to nonocclusive lesions.33 These
findings may favor prolonged administration of dual antiplate-
let therapy, in an attempt to reduce the risk of stent
thrombosis.34
Solid-state, phased-array catheters (Eagle-Eye, Volcano)
are preferred over rotational IVUS systems, because the
imaging transducer is closer to the tip of the IVUS catheter. A
short-tip solid-state IVUS catheter (Eagle Eye Short Tip,
Volcano) is advantageous for imaging in CTO PCI, as it
minimizes the extent of distal advancement required for distal
imaging and may be more deliverable.10
Imaging for CTO Crossing
Intravascular imaging can assist CTO crossing by (1) identifying
the proximal cap in cases with proximal cap ambiguity (for
example, by imaging through a side branch adjacent to the
occlusion)4; (2) confirming whether the antegrade guidewire
Table 2. Angiographic Characteristics Classified According to Whether Intravascular Imaging was Used to Guide CTO Crossing or
Not
Variable
Overall
Imaging for
Crossing
No Imaging or Imaging
for Stent Optimization
P-Value(n=619) (n=111) (n=508)
CTO target vessel 0.861
RCA 52% 51% 52%
LAD 26% 28% 26%
LCX 22% 21% 22%
Successful crossing strategy <0.0001
Antegrade wiring 48% 23% 53%
Retrograde 23% 47% 17%
Antegrade dissection and re-entry 23% 25% 23%
None 6% 5% 7%
First crossing strategy 0.889
Antegrade wiring 78% 78% 78%
Retrograde 14% 15% 14%
Antegrade dissection and re-entry 8% 6% 8%
Retrograde crossing attempt 37% 67% 31% <0.0001
J-CTO score* 2.511.20 2.861.19 2.431.19 0.001
P-CTO score* 1.371.01 1.641.00 1.181.02 <0.0001
Calcification (moderate/severe) 53% 60% 51% 0.103
Tortuosity (moderate/severe) 42% 48% 40% 0.126
Proximal cap ambiguity 31% 49% 26% <0.0001
In-stent restenosis 17% 20% 16% 0.334
Prior failure to open CTO 16% 21% 15% 0.147
Interventional collaterals 53% 52% 53% 0.794
Side branch at the proximal cap 50% 61% 47% 0.009
Blunt/no stump, % 57% 68% 55% 0.009
Vessel diameter, mm† 2.6 (2.5, 3.0) 2.5 (2.5, 3.0) 2.7 (2.5, 3.0) 0.684
Occlusion length, mm† 30 (19, 45) 30 (22, 50) 30 (18, 40) 0.093
Number of stents used 2.531.2 2.781.4 2.481.19 0.047
Imaging for crossing: cases in which intravascular imaging was used for crossing the chronic total occlusion. No imaging or imaging for stent optimization: cases in which intravascular
imaging was not used or cases in which intravascular imaging was used for stent optimization. CTO indicates chronic total occlusion; J-CTO score, Japanese chronic total occlusion score;
LAD, left anterior descending artery; LCX, left circumflex artery; P-CTO score, Progress chronic total occlusion score; RCA, right coronary artery.
*MeanSD.
†Median (interquartile range).
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has engaged the occlusion and navigating the antegrade
guidewire to the true lumen in case of dissection5,35; (3)
confirming that the retrograde guidewire has entered the
proximal true lumen before externalization; and (4) determining
the appropriate balloon size for the CART and reverse CART
techniques.10,11 Moreover, use of IVUS could assist re-entry
into the distal true lumen after subintimal crossing35 and
reduce the need for fluoroscopy and contrast injection.5 In our
study, 3 characteristics of CTOs were associated with
IVUS utilization during crossing: side branch at proximal cap
Table 3. Procedural Outcomes of the Study Patients, Classified According to Whether Intravascular Imaging was Used to Guide
CTO Crossing or Not
Variable Overall
Imaging for
Crossing
No Imaging or Imaging
for Stent Optimization P-Value
Technical success 90.1% 92.8% 89.6% 0.302
Procedural success 88.6% 90.1% 88.3% 0.588
Procedural time, minute* 142 (96, 210) 192 (130, 255) 131 (90, 192) <0.0001
Fluoroscopy time, minute* 45 (27, 75) 71 (44, 93) 39 (25, 69) <0.0001
Air kerma radiation dose (Gray)* 3.59 (2.27, 5.40) 4.98 (3.11, 6.04) 3.42 (2.09, 5.09) <0.0001
Contrast volume* 280 (205, 367) 310 (240, 400) 270 (200, 360) 0.004
MACE 3.1% 2.7% 3.2% 0.772
Death 0.5% 0.0% 0.6% 0.411
Acute Q wave MI 0% 0% 0.0% —
Acute MI 1.3% 1.8% 1.2% 0.623
Re-PCI 0.3% 0.0% 0.4% 0.502
Stroke 0.4% 0.0% 0.6% 0.411
Emergency CABG 0% 0% 0.0% —
Pericardiocentesis 0.9% 0.9% 1.0% 0.916
Imaging for crossing: cases in which intravascular imaging was used for crossing the chronic total occlusion; No imaging or imaging for stent optimization: cases in which intravascular
imaging was not used or cases in which intravascular imaging was used for stent optimization. CABG indicates coronary artery bypass grafting; CTO, chronic total occlusion; MACE, major
adverse cardiac events; MI, myocardial infarction; PCI, percutaneous coronary intervention.
*Median (interquartile range).
Figure 4. Technical, procedural success and MACE among study procedures classified according to use
of intravascular imaging for crossing. MACE indicates major cardiac adverse event.
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(61% versus 47%, P=0.009), proximal cap ambiguity (49%
versus 26%, P<0.001), and blunt/no stump (68% versus 55%,
0.009).
Park et al reported that the IVUS-guided wiring technique
was useful and safe for antegrade recanalization of 31
stumpless CTOs (Table 6). The IVUS catheter was advanced
into the side branch to identify the CTO entry point, while
another stiffer guidewire was directed under IVUS guidance to
the occlusion entry point and penetrated the proximal cap. In
case of subintimal position of the guidewire, IVUS was also
used to redirect the wire into the true lumen. However, this
technique has 2 potential limitations: first, IVUS cannot
provide information on the course of the vessel distal to the
occlusion (dual injection can be used to visualize the entire
course of the vessel distal to the occlusion); second, IVUS-
guided wiring cannot be applied in cases without appropriate
side branches (for example, with smaller vessel diameter than
the IVUS catheters).4
IVUS may be particularly useful for the retrograde
approach to CTO crossing, as retrograde cases are often
more complex than antegrade-only cases due to difficulties
crossing the collateral and/or crossing the occlusion and
Table 4. Angiographic Characteristics Classified According to Whether or Not Intravascular Imaging Technique Was Used for Stent
Optimization
Variable
Overall
Imaging for Stent
Optimization
No Imaging or Imaging
for Crossing Only
P-Value(n=568) (n=175) (n=393)
CTO target vessel 0.137
RCA 51% 49% 52%
LAD 27% 32% 25%
LCX 22% 19% 23%
Successful crossing strategy 0.001
Antegrade wiring 51% 42% 55%
Retrograde 24% 27% 23%
Antegrade dissection and re-entry 25% 31% 22%
First crossing strategy 0.321
Antegrade wiring 78% 77% 79%
Retrograde 14% 13% 14%
Antegrade dissection and re-entry 8% 10% 7%
Retrograde crossing attempt 36% 45% 32% 0.003
J-CTO score* 2.471.21 2.651.17 2.381.22 0.013
Progress CTO score* 1.251.02 1.391.09 1.190.98 0.035
Calcification (moderate/severe) 52% 63% 47% 0.001
Tortuosity (moderate/severe) 41% 42% 40% 0.742
Proximal cap ambiguity 30% 34% 28% 0.155
In-stent restenosis 17% 23% 14% 0.015
Prior failure to open CTO 16% 18% 15% 0.429
Interventional Collaterals 53% 52% 54% 0.648
Side branch at the proximal cap 49% 50% 48% 0.753
Blunt/no stump 55% 50% 57% 0.123
Vessel diameter, mm† 2.5 (2.5, 3.0) 2.8 (2.5, 3) 2.5 (2.5, 3) 0.257
Occlusion length, mm† 30 (18, 45) 30 (20, 50) 28 (15, 40) 0.03
Number of stents used 2.51.2 2.71.3 2.51.2 0.076
Imaging for stent optimization: cases in which intravascular imaging was used for stent optimization. No imaging or imaging for crossing only: cases in which intravascular imaging was not
used or cases in which intravascular imaging was used only for crossing the chronic total occlusion. CTO indicates chronic total occlusion; J-CTO score, Japanese chronic total occlusion
score; LAD, left anterior descending artery; LCX, left circumflex artery; P-CTO score, Progress chronic total occlusion score; RCA, right coronary artery.
*MeanSD.
†Median (interquartile range).
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externalizing the guidewire. Indeed, IVUS was used in 67% of
retrograde versus 31% of antegrade-only cases in our study
(P<0.0001). IVUS can clarify the location of guidewires and
guide balloon size selection when performing reverse CART.
Dai et al showed that the IVUS-guided reverse CART approach
is efficient and safe for revascularization of complex CTOs.
Table 5. Procedural Outcomes of the Study Patients, Classified According to Whether Intravascular Imaging was Used for Stent
Optimization or Not
Variable Overall
Imaging for Stent
Optimization
No Imaging or Imaging
for Crossing Only P-Value
Technical success 97.5% 97.7% 97.5% 0.854
Procedural success 95.9% 97.1% 95.4% 0.347
Procedural time, min* 143 (97, 205) 162 (113, 216) 133 (91, 201) 0.001
Fluoroscopy time, min* 44 (27, 75) 52 (33, 81) 40 (26, 73) 0.014
Air kerma radiation dose (Gray)* 3.60 (2.24, 5.37) 3.90 (2.48, 5.46) 3.48 (2.13, 5.34) 0.249
Contrast volume* 282 (205, 369) 300 (228, 368) 277 (200, 370) 0.106
MACE 2.9% 2.3% 3.1% 0.622
Death 0.4% 0.0% 0.5% 0.347
Acute Q wave MI 0% 0% 0.0%
Acute MI 1.3% 0.6% 1.6% 0.346
Re-PCI 0.4% 0.0% 0.5% 0.347
Stroke 0.7% 0.6% 0.8% 0.808
Emergency CABG 0% 0% 0.0%
Pericardiocentesis 0.7% 1.2% 0.5% 0.398
Imaging for stent optimization: cases in which intravascular imaging was used for stent optimization. No imaging or imaging for crossing only: cases in which intravascular imaging was not
used or cases in which intravascular imaging was used only for crossing the chronic total occlusion. CABG, coronary artery bypass graft; MACE, major adverse cardiac events; MI,
myocardial infarction; PCI, percutaneous coronary intervention.
*Median (interquartile range).
Figure 5. Technical, procedural success and major cardiac adverse events according to purpose of
intravascular imaging techniques. IMG indicates imaging; MACE, major cardiac adverse events.
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They overlapped an antegrade and a retrograde guidewire
within the occlusion and inflated a small balloon (1.2–
1.5 mm) to create an antegrade subintimal or intimal
dissection. The IVUS catheter was then advanced into the
dissection plane to guide crossing of the occlusion.11
Imaging for Stent Optimization
Intravascular imaging can assist with optimizing stent diam-
eter and length selection, and further ensure that optimal
expansion has occurred.10 Two randomized-controlled trials
have compared IVUS guidance versus angiographic guidance
for stent optimization after CTO PCI. Kim et al randomized
402 patients to IVUS guidance versus angiographic guidance
and found that IVUS guidance reduced the subsequent
incidence of MACE.3 Similarly, Tian et al in the AIR-CTO
(Angiographic and clinical comparisons of intravascular ultra-
sound- versus angiography-guided drug-eluting stent implan-
tation for patients with Chronic Total Occlusion lesions) study
randomized 230 patients to IVUS or angiographic guidance
and found that IVUS guidance was associated with lower in-
stent late lumen loss at 1-year angiographic and IVUS follow-
up, leading to less frequent restenosis and lower rates of
stent thrombosis.2 These findings are in agreement with the
findings of the IVUS-XPL (The Impact of Intravascular
Ultrasound Guidance on Outcomes of Xience Prime Stents
in Long Lesions) study that randomized 1400 patients to
undergo IVUS-guided or angiography-guided everolimus-elut-
ing stent implantation in non-CTO long lesions and resulted in
a significantly lower rate of 12-month MACE, primarily driven
by lower risk for target lesion revascularization.36 Use of
intravascular imaging (either IVUS or OCT) can help identify
and treat stent underexpansion, which is an important risk
factor for both restenosis6 and stent thrombosis. Use of
intravascular imaging may be of particular importance in long
and calcified CTOs. In our study we observed a trend toward a
higher number of stents in procedures guided by IVUS. This
could be related to higher lesion complexity among imaged
Table 6. Summary of Published Reports of Intravascular Ultrasound Use in CTO PCI
Author Year
No. of
Patients
No. of
Lesions
Imaging
Frequency Comments
Intravascular imaging for crossing
Antegrade
crossing
Park et al4 2011 31 32 100% IVUS-guided wiring is technically feasible and safe for recanalization of
stumpless CTO lesions
Ito et al35 2004 2 2 100% Case report: (1) IVUS advanced into a side branch to identify the entry
point of the major branch (2) IVUS-guided penetration of the
guidewire from the false lumen to the true lumen after dissection
Matsubara et al5 2004 2 2 100% Case report: (1) IVUS catheter in the subintima was used to guide the
wire into the true lumen. (2) The orifice of the LAD was identified by
imaging with IVUS in a diagonal branch
Retrograde
crossing
Dai et al11 2013 49 49 100% IVUS-guided reverse CART approach is efficient and safe for
revascularization of complex CTOs
Intravascular imaging for stent optimization
Retrospective
studies
Kang et al6 2015 126 126 100% Among patients in whom IVUS was used post CTO PCI, post CTO-PCI
angiographic minimum luminal diameter ≤2.4 mm and stent
expansion ratio ≤70% as assessed by IVUS were both independent
predictors of in-stent restenosis
Hong et al1 2014 534 534 50% IVUS was used in 39% of CTO PCI and was associated with lower risk
for stent thrombosis and a trend for lower incidence of myocardial
infarction as compared with angiography-guided CTO PCI
Tsujita et al32 2009 48 48 100% Compared antegrade and retrograde approaches with IVUS after
crossing; IVUS can be a useful tool for the detection of procedure-
related vessel damage and subintimal wire tracking
Prospective
randomized-
controlled
clinical trials
Kim et al3 2015 402 402 50% Randomized-controlled trial of IVUS guidance in CTO PCI demonstrating
lower 12-month incidence of MACE in the IVUS-guidance group
Tian et al2 2015 230 230 50% Randomized-controlled trial of IVUS guidance in CTO PCI demonstrating
that IVUS guidance was associated with less late lumen loss and a
lower incidence of 12-month in-stent restenosis
CART indicates controlled antegrade and retrograde tracking and dissection; CTO, chronic total occlusion; IVUS, intravascular ultrasound; LAD, left anterior descending artery; MACE, major
adverse cardiac events; PCI, percutaneous coronary intervention.
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lesions, but could also indicate increased detection of
dissection flaps, gaps between stents, or untreated residual
coronary disease that might have not been apparent during
diagnostic angiography.
Intravascular Imaging and Contrast Use
Mariani et al in the MOZART (Minimizing cOntrast utilization
With IVUS Guidance in CoRonary angioplasTy) trial found that
IVUS as a primary imaging tool to guide PCI was safe and
markedly reduced the volume of iodine contrast as compared
with angiography-guided PCI.37 Dai et al suggested that the
IVUS-guided reverse CART technique could reduce the
contrast volume.11 However, in our study contrast volume
was higher among cases in which intravascular imaging was
used for crossing, likely reflecting the higher complexity of
such cases.
Study Limitations
Our study has potential limitations. First, PROGRESS CTO is
an observational registry without adjudication of clinical
events by an independent event committee. Second, quanti-
tative coronary angiographic analysis was not performed and
therefore assessment of angiographic characteristics was
subject to operator-related bias. Third, procedures were
performed by experienced operators in CTO PCI, limiting
extrapolation of the study results to less experienced centers
and operators. Fourth, use of intravascular imaging was
performed at the discretion of the operator, with high
variability between centers. Fifth, few patients (n=13) had
more than 1 CTO PCI.
Conclusion
In summary, intravascular imaging is frequently performed
during CTO PCI both for crossing and for stent selection/
optimization. Even though intravascular imaging was used in
more complex lesions, it was associated with similar rates of
technical and procedural success, but higher use of radiation
and longer procedure time.
Acknowledgments
Study data were collected and managed using REDCap electronic
data capture tools hosted at University of Texas Southwestern
Medical Center.38 REDCap (Research Electronic Data Capture) is a
secure, web-based application designed to support data capture for
research studies, providing (1) an intuitive interface for validated data
entry; (2) audit trails for tracking data manipulation and export
procedures; (3) automated export procedures for seamless data
downloads to common statistical packages; and (4) procedures for
importing data from external sources.
Sources of Funding
This was work was supported by Clinical and Translational
Science Awards National Institutes of Health Grant UL1-
RR024982.
Disclosures
Dr Alaswad receives consulting fees from Terumo and Boston
Scientific; and is an uncompensated consultant to Abbott
Laboratories. Dr Jaffer is a consultant to Boston Scientific,
Siemens, and Merck, receives nonfinancial research support
from Abbott Vascular, and research grant from National
Institutes of Health (HL-R01-108229). Dr Yeh receives Career
Development Award (1K23HL118138) from the National Heart,
Lung, and Blood Institute. Dr Grantham receives speaking fees,
consulting, and honoraria from Boston Scientific and Asahi
Intecc; and Research grants from Boston Scientific, Asahi
Intecc, Abbott Vascular, and Medtronic. Dr Karmpaliotis is a
member of the speaker bureau for Abbott Vascular, Medtronic,
and Boston Scientific. Dr Kirtane receives Institutional research
grants to Columbia University from Boston Scientific, Med-
tronic, Abbott Vascular, Abiomed, St. Jude Medical, Vascular
Dynamics, Glaxo SmithKline, and Eli Lilly. Dr Parikh is amember
of the speaker bureau for Abbot Vascular, Medtronic, CSI, BSc;
and a member of the advisory boards of Medtronic, Abbott
Vascular, and Philips. Dr Ali receives grant support and is a
consultant for St Jude Medical and InfraReDx. Dr Lombardi has
equity with Bridgepoint Medical. Dr Kandzari receives
research/grant support and consulting honoraria from Boston
Scientific and Medtronic Cardiovascular, and research/grant
support from Abbott. Dr Lembo is a member of the speaker
bureau of Medtronic and advisory board for Abbott Vascular
and Medtronic. Dr Garcia receives consulting fees from
Medtronic. Dr Wyman receives Honoraria/consulting/speak-
ing fees from Boston Scientific, Abbott Vascular, and Asahi. Dr
Rangan receives Research grants from InfraReDx, Inc., and The
Spectranetics Corporation. Dr Thompson is an employee of
Boston Scientific. Dr Banerjee receives research grants from
Gilead and the Medicines Company; consultant/speaker
honoraria from Covidien and Medtronic; has ownership in
MDCARE Global (spouse) and intellectual property in HygeiaTel.
Dr Brilakis receives consulting/speaker honoraria from Abbott
Vascular, Asahi, Cardinal Health, GE Healthcare, Elsevier, and
St Jude Medical; and research support from Boston Scientific
and InfraRedx. His spouse is an employee of Medtronic. The
remaining authors have no disclosures to report.
References
1. Hong SJ, Kim BK, Shin DH, Kim JS, Hong MK, Gwon HC, Kim HS, Yu CW, Park
HS, Chae IH, Rha SW, Lee SH, Kim MH, Hur SH, Jang Y. Usefulness of
intravascular ultrasound guidance in percutaneous coronary intervention with
second-generation drug-eluting stents for chronic total occlusions (from the
DOI: 10.1161/JAHA.116.003890 Journal of the American Heart Association 11
Intravascular Imaging in CTO PCI Karacsonyi et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Multicenter Korean-Chronic Total Occlusion Registry). Am J Cardiol.
2014;114:534–540.
2. Tian NL, Gami SK, Ye F, Zhang JJ, Liu ZZ, Lin S, Ge Z, Shan SJ, You W, Chen L,
Zhang YJ, Mintz G, Chen SL. Angiographic and clinical comparisons of
intravascular ultrasound- versus angiography-guided drug-eluting stent implan-
tation for patients with chronic total occlusion lesions: two-year results from a
randomised AIR-CTO study. EuroIntervention. 2015;10:1409–1417.
3. Kim BK, Shin DH, Hong MK, Park HS, Rha SW, Mintz GS, Kim JS, Lee SJ, Kim
HY, Hong BK, Kang WC, Choi JH, Jang Y. Clinical impact of intravascular
ultrasound-guided chronic total occlusion intervention with zotarolimus-eluting
versus biolimus-eluting stent implantation: randomized study. Circ Cardiovasc
Interv. 2015;8:e002592.
4. Park Y, Park HS, Jang GL, Lee DY, Lee H, Lee JH, Kang HJ, Yang DH, Cho Y,
Chae SC, Jun JE, Park WH. Intravascular ultrasound guided recanalization of
stumpless chronic total occlusion. Int J Cardiol. 2011;148:174–178.
5. Matsubara T, Murata A, Kanyama H, Ogino A. Ivus-guided wiring technique:
promising approach for the chronic total occlusion. Catheter Cardiovasc Interv.
2004;61:381–386.
6. Kang J, Cho YS, Kim SW, Park JJ, Yoon YE, Oh IY, Yoon CH, Suh JW, Youn TJ,
Chae IH, Choi DJ. Intravascular ultrasound and angiographic predictors of in-
stent restenosis of chronic total occlusion lesions. PLoS One. 2015;10:
e0140421.
7. Fujii K, Ochiai M, Mintz GS, Kan Y, Awano K, Masutani M, Ashida K, Ohyanagi
M, Ichikawa S, Ura S, Araki H, Stone GW, Moses JW, Leon MB, Carlier SG.
Procedural implications of intravascular ultrasound morphologic features of
chronic total coronary occlusions. Am J Cardiol. 2006;97:1455–1462.
8. Wallace EL, Ziada KM. Intravascular-ultrasound assisted localization and
revascularization of an ostial chronic total occlusion: utility of near-field and
far-field imaging. J Invasive Cardiol. 2015;27:E37–E39.
9. Nakashima M, Ikari Y, Aoki J, Tanabe K, Tanimoto S, Hara K. Intravascular
ultrasound-guided chronic total occlusion wiring technique using 6 Fr
catheters via bilateral transradial approach. Cardiovasc Interv Ther.
2015;30:68–71.
10. Brilakis ES. Manual of Chronic Total Occlusion Interventions. A Step-by-Step
Approach. Waltham, MA: Elsevier; 2013.
11. Dai J, Katoh O, Kyo E, Tsuji T, Watanabe S, Ohya H. Approach for chronic total
occlusion with intravascular ultrasound-guided reverse controlled antegrade
and retrograde tracking technique: single center experience. J Interv Cardiol.
2013;26:434–443.
12. Rathore S, Katoh O, Tuschikane E, Oida A, Suzuki T, Takase S. A novel
modification of the retrograde approach for the recanalization of chronic total
occlusion of the coronary arteries intravascular ultrasound-guided reverse
controlled antegrade and retrograde tracking. JACC Cardiovasc Interv.
2010;3:155–164.
13. Estevez-Loureiro R, Ghione M, Kilickesmez K, Agudo P, Lindsay A, Di Mario C.
The role for adjunctive image in pre-procedural assessment and peri-
procedural management in chronic total occlusion recanalisation. Curr Cardiol
Rev. 2014;10:120–126.
14. Christopoulos G, Karmpaliotis D, Alaswad K, Yeh RW, Jaffer FA, Wyman RM,
Lombardi WL, Menon RV, Grantham JA, Kandzari DE, Lembo N, Moses JW,
Kirtane AJ, Parikh M, Green P, Finn M, Garcia S, Doing A, Patel M, Bahadorani J,
Tarar MN, Christakopoulos GE, Thompson CA, Banerjee S, Brilakis ES.
Application and outcomes of a hybrid approach to chronic total occlusion
percutaneous coronary intervention in a contemporary multicenter US
registry. Int J Cardiol. 2015;198:222–228.
15. Christopoulos G, Karmpaliotis D, Wyman MR, Alaswad K, McCabe J, Lombardi
WL, Grantham JA, Marso SP, Kotsia AP, Rangan BV, Garcia SA, Lembo N,
Kandzari D, Lee J, Kalynych A, Carlson H, Thompson CA, Banerjee S, Brilakis
ES. Percutaneous intervention of circumflex chronic total occlusions is
associated with worse procedural outcomes: insights from a multicentre US
registry. Can J Cardiol. 2014;30:1588–1594.
16. Christopoulos G, Menon RV, Karmpaliotis D, Alaswad K, Lombardi W,
Grantham A, Patel VG, Rangan BV, Kotsia AP, Lembo N, Kandzari D, Carlson
H, Garcia S, Banerjee S, Thompson CA, Brilakis ES. The efficacy and safety of
the “hybrid” approach to coronary chronic total occlusions: insights from a
contemporary multicenter US registry and comparison with prior studies. J
Invasive Cardiol. 2014;26:427–432.
17. Sapontis J, Christopoulos G, Grantham JA, Wyman RM, Alaswad K, Karmpali-
otis D, Lombardi WL, McCabe JM, Marso SP, Kotsia AP, Rangan BV,
Christakopoulos GE, Garcia S, Thompson CA, Banerjee S, Brilakis ES.
Procedural failure of chronic total occlusion percutaneous coronary interven-
tion: insights from a multicenter US registry. Catheter Cardiovasc Interv.
2015;85:1115–1122.
18. Alaswad K, Menon RV, Christopoulos G, Lombardi WL, Karmpaliotis D,
Grantham JA, Marso SP, Wyman MR, Pokala NR, Patel SM, Kotsia AP, Rangan
BV, Lembo N, Kandzari D, Lee J, Kalynych A, Carlson H, Garcia SA, Thompson
CA, Banerjee S, Brilakis ES. Transradial approach for coronary chronic total
occlusion interventions: insights from a contemporary multicenter registry.
Catheter Cardiovasc Interv. 2015;85:1123–1129.
19. Christopoulos G, Wyman RM, Alaswad K, Karmpaliotis D, Lombardi W,
Grantham JA, Yeh RW, Jaffer FA, Cipher DJ, Rangan BV, Christakopoulos GE,
Kypreos MA, Lembo N, Kandzari D, Garcia S, Thompson CA, Banerjee S,
Brilakis ES. Clinical utility of the Japan-chronic total occlusion score in
coronary chronic total occlusion interventions: results from a multicenter
registry. Circ Cardiovasc Interv. 2015;8:e002171.
20. Christopoulos G, Menon RV, Karmpaliotis D, Alaswad K, Lombardi W,
Grantham JA, Michael TT, Patel VG, Rangan BV, Kotsia AP, Lembo N, Kandzari
DE, Lee J, Kalynych A, Carlson H, Garcia S, Banerjee S, Thompson CA, Brilakis
ES. Application of the “hybrid approach” to chronic total occlusions in patients
with previous coronary artery bypass graft surgery (from a contemporary
multicenter US registry). Am J Cardiol. 2014;113:1990–1994.
21. Christopoulos G, Karmpaliotis D, Alaswad K, Lombardi WL, Grantham JA,
Rangan BV, Kotsia AP, Lembo N, Kandzari DE, Lee J, Kalynych A, Carlson H,
Garcia S, Banerjee S, Thompson CA, Brilakis ES. The efficacy of “hybrid”
percutaneous coronary intervention in chronic total occlusions caused by in-
stent restenosis: insights from a US multicenter registry. Catheter Cardiovasc
Interv. 2014;84:646–651.
22. Christopoulos G, Kandzari DE, Yeh RW, Jaffer FA, Karmpaliotis D, Wyman MR,
Alaswad K, Lombardi W, Grantham JA, Moses J, Christakopoulos G, Tarar MN,
Rangan BV, Lembo N, Garcia S, Cipher D, Thompson CA, Banerjee S, Brilakis
ES. Development and validation of a novel scoring system for predicting
technical success of chronic total occlusion percutaneous coronary interven-
tions: the PROGRESS CTO (prospective global registry for the study of chronic
total occlusion intervention) score. JACC Cardiovasc Interv. 2016;9:1–9.
23. Karacsonyi J, Karatasakis A, Karmpaliotis D, Alaswad K, Yeh RW, Jaffer FA,
Wyman MR, Lombardi WL, Grantham JA, Kandzari DE, Lembo N, Moses JW,
Kirtane AJ, Parikh MA, Green P, Finn M, Garcia S, Doing A, Patel M, Bahadorani
J, Martinez Parachini JR, Resendes E, Rangan BV, Ungi I, Thompson CA,
Banerjee S, Brilakis ES. Effect of previous failure on subsequent procedural
outcomes of chronic total occlusion percutaneous coronary intervention (from
a contemporary multicenter registry). Am J Cardiol. 2016;117:1267–1271.
24. Danek BA, Karatasakis A, Karmpaliotis D, Alaswad K, Yeh RW, Jaffer FA, Patel
M, Bahadorani J, Lombardi WL, Wyman MR, Grantham JA, Doing A, Moses JW,
Kirtane A, Parikh M, Ali ZA, Kalra S, Kandzari DE, Lembo N, Garcia S, Rangan
BV, Thompson CA, Banerjee S, Brilakis ES. Use of antegrade dissection re-
entry in coronary chronic total occlusion percutaneous coronary intervention
in a contemporary multicenter registry. Int J Cardiol. 2016;214:428–437.
25. Stone GW, Reifart NJ, Moussa I, Hoye A, Cox DA, Colombo A, Baim DS,
Teirstein PS, Strauss BH, Selmon M, Mintz GS, Katoh O, Mitsudo K, Suzuki T,
Tamai H, Grube E, Cannon LA, Kandzari DE, Reisman M, Schwartz RS, Bailey S,
Dangas G, Mehran R, Abizaid A, Moses JW, Leon MB, Serruys PW.
Percutaneous recanalization of chronically occluded coronary arteries: a
consensus document: part II. Circulation. 2005;112:2530–2537.
26. Morino Y, Kimura T, Hayashi Y, Muramatsu T, Ochiai M, Noguchi Y, Kato K,
Shibata Y, Hiasa Y, Doi O, Yamashita T, Morimoto T, Abe M, Hinohara T,
Mitsudo K. In-hospital outcomes of contemporary percutaneous coronary
intervention in patients with chronic total occlusion insights from the J-CTO
Registry (Multicenter CTO Registry in Japan). JACC Cardiovasc Interv.
2010;3:143–151.
27. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus
HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood
R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M,
Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J,
Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Januzzi JL, Nieminen
MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD,
Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D,
Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal
definition of myocardial infarction. Circulation. 2012;126:2020–2035.
28. Okamura A, Yamane M, Muto M, Matsubara T, Igarashi Y, Nakamura S,
Muramatsu T, Fujita T, Oida A, Tsuchikane E. Complications during retrograde
approach for chronic coronary total occlusion: Sub-analysis of japanese
multicenter registry. Catheter Cardiovasc Interv. 2016;88:7–14.
29. Galassi AR, Tomasello SD, Reifart N, Werner GS, Sianos G, Bonnier H, Sievert
H, Ehladad S, Bufe A, Shofer J, Gershlick A, Hildick-Smith D, Escaned J, Erglis
A, Sheiban I, Thuesen L, Serra A, Christiansen E, Buettner A, Costanzo L,
Barrano G, Di Mario C. In-hospital outcomes of percutaneous coronary
intervention in patients with chronic total occlusion: insights from the ERCTO
(European Registry of Chronic Total Occlusion) Registry. EuroIntervention.
2011;7:472–479.
30. Galassi AR, Sianos G, Werner GS, Escaned J, Tomasello SD, Boukhris M,
Castaing M, Buttner JH, Bufe A, Kalnins A, Spratt JC, Garbo R, Hildick-Smith D,
Elhadad S, Gagnor A, Lauer B, Bryniarski L, Christiansen EH, Thuesen L, Meyer-
Gessner M, Goktekin O, Carlino M, Louvard Y, Lefevre T, Lismanis A, Gelev VL,
Serra A, Marza F, Di Mario C, Reifart N. Retrograde recanalization of chronic
DOI: 10.1161/JAHA.116.003890 Journal of the American Heart Association 12
Intravascular Imaging in CTO PCI Karacsonyi et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
total occlusions in europe: procedural, in-hospital, and long-term outcomes
from the multicenter ERCTO registry. J Am Coll Cardiol. 2015;65:2388–2400.
31. Habara M, Tsuchikane E, Muramatsu T, Kashima Y, Okamura A, Mutoh M,
Yamane M, Oida A, Oikawa Y, Hasegawa K. Comparison of percutaneous
coronary intervention for chronic total occlusion outcome according to
operator experience from the Japanese retrograde summit registry. Catheter
Cardiovasc Interv. 2016;87:1027–1035.
32. Tsujita K, Maehara A, Mintz GS, Kubo T, Doi H, Lansky AJ, Stone GW, Moses
JW, Leon MB, Ochiai M. Intravascular ultrasound comparison of the retrograde
versus antegrade approach to percutaneous intervention for chronic total
coronary occlusions. JACC Cardiovasc Interv. 2009;2:846–854.
33. Heeger CH, Busjahn A, Hildebrand L, Fenski M, Lesche F, Meincke F, Kuck KH,
Bergmann MW. Delayed coverage of drug-eluting stents after interventional
revascularisation of chronic total occlusions assessed by optical coherence
tomography: the ALSTER-OCT-CTO registry. EuroIntervention. 2016;11:1004–
1012.
34. Niccoli G, Ferrante G, Galassi AR, Montone RA, Crea F. Optical coherence
tomography follow-up of the subintimal tracking and re-entry technique for
chronic total occlusion. EuroIntervention. 2010;6:662–663.
35. Ito S, Suzuki T, Ito T, Katoh O, Ojio S, Sato H, Ehara M, Kawase Y, Myoishi M,
Kurokawa R, Ishihara Y, Suzuki Y, Sato K, Toyama J, Fukutomi T, Itoh M. Novel
technique using intravascular ultrasound-guided guidewire cross in coronary
intervention for uncrossable chronic total occlusions. Circ J. 2004;68:1088–
1092.
36. Hong SJ, Kim BK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Kang WC,
Her AY, Kim YH, Hur SH, Hong BK, Kwon H, Jang Y, Hong MK. Effect of
intravascular ultrasound-guided vs angiography-guided everolimus-eluting
stent implantation: the IVUS-XPL randomized clinical trial. JAMA.
2015;314:2155–2163.
37. Mariani J Jr, Guedes C, Soares P, Zalc S, Campos CM, Lopes AC, Spadaro AG,
Perin MA, Filho AE, Takimura CK, Ribeiro E, Kalil-Filho R, Edelman ER, Serruys
PW, Lemos PA. Intravascular ultrasound guidance to minimize the use of
iodine contrast in percutaneous coronary intervention: the MOZART (minimiz-
ing contrast utilization with IVUS guidance in coronary angioplasty) random-
ized controlled trial. JACC Cardiovasc Interv. 2014;7:1287–1293.
38. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (redcap)–a metadata-driven methodology and work-
flow process for providing translational research informatics support. J Biomed
Inform. 2009;42:377–381.
DOI: 10.1161/JAHA.116.003890 Journal of the American Heart Association 13
Intravascular Imaging in CTO PCI Karacsonyi et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
